Therapeutic Issues for Autism Spectrum Disorders: a Clinical Trial
Description:
Autism spectrum disorders (ASDs) are clinical disorders with multiple developmental
disabilities in skills associated with overall behavior and communication. The term (ASD)
includes Autistic Disorder (AD), Pervasive Developmental Disorder-Not Otherwise Specified
(PDD-NOS), and Asperger’s Disorder .
Hyperbaric oxygen therapy (HBOT) is a treatment in which patients inside a hyperbaric chamber
breathe a concentrated oxygen pressurized more than sea level (1 atmosphere absolute) .
It was obvious that autistic children may have some benefits of HBOT by increasing in
cerebral perfusion during treatment. Inhalation of more pressurized oxygen might elevate
partial pressure of oxygen in the arterial blood, and increased oxygen that reaches the brain
. Another mechanism of action of HBOT that it might have anti-inflammatory properties by
reduction of pro-inflammatory cytokines, interleukins 1 and 6, interferon-γ, and tumor
necrosis factor-α. Furthermore, HBOT might enhance mitochondrial dysfunction, and upregulate
the antioxidant enzymes production.
Risperidone is a second generation antipsychotic, approved by the Food and Drug
Administration (FDA) for treatment of autism-related irritability. Its approved in 2006 only
for children not less than 5 years old . This trial aimed to study the effects of hyperbaric
oxygen therapy and/or Risperidone in management symptoms of autism.
Condition:
Autism Spectrum Disorder
Treatment:
Risperidone
Start Date:
January 2016
Sponsor:
Minia University
For More Information:
https://clinicaltrials.gov/show/NCT03887754